Change of Serum Antithyroglobulin Antibody Levels Is Useful for Prediction of Clinical Recurrence in Thyroglobulin-Negative Patients with Differentiated Thyroid Carcinoma

被引:179
作者
Kim, Won Gu [1 ]
Yoon, Jong Ho [4 ]
Kim, Won Bae [1 ]
Kim, Tae Yong [1 ]
Kim, Eui Young [1 ]
Kim, Jung Min [5 ]
Ryu, Jin-Sook [2 ]
Gong, Gyungyub [3 ]
Hong, Suck Joon [4 ]
Shong, Young Kee [1 ]
机构
[1] Univ Ulsan, Coll Med, Asan Med Ctr, Dept Endocrinol & Metab, Seoul 138736, South Korea
[2] Univ Ulsan, Coll Med, Asan Med Ctr, Dept Nucl Med, Seoul 138736, South Korea
[3] Univ Ulsan, Coll Med, Asan Med Ctr, Dept Pathol, Seoul 138736, South Korea
[4] Univ Ulsan, Coll Med, Asan Med Ctr, Dept Surg, Seoul 138736, South Korea
[5] Natl Canc Ctr, Thyroid Canc Clin, Goyang 410769, South Korea
关键词
D O I
10.1210/jc.2008-0962
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Objectives: The aim of the study was to evaluate the usefulness of the antithyroglobulin autoantibody (TgAb) value at 6-12 months after remnant ablation in predicting recurrence in differentiated thyroid carcinoma patients who had undetectable thyroglobulin (Tg) values. The change in TgAb concentration measured between the time of remnant ablation (TgAb1) and 6-12 months thereafter (TgAb2) was also evaluated as a possible prognostic indicator. Patients and Methods: Patients with differentiated thyroid carcinoma who underwent total thyroidectomy followed by I-131 remnant ablation between 1995 and 2003 at the Asan Medical Center (Seoul, Korea) were enrolled. Of these, 824 patients with undetectable Tg at 6-12 months after remnant ablation during thyroid hormone withdrawal were the subjects of this study. Results: TgAb2 was positive in 56 patients. Ten of 56 patients (18%) with positive TgAb2 had recurrence, whereas only 10 of 768 patients (1%) with negative TgAb2 had recurrence during 73.6 months of follow-up (P < 0.001). The change between TgAb1 and TgAb2 levels was evaluated in patients with positive TgAb2. TgAb concentration decreased by more than 50% in 21 patients (group 1) and by less than 50% in 16 patients (group 2), and it increased in 19 patients (group 3). The recurrence rates in groups 1, 2, and 3 were 0, 19, and 37%, respectively (P = 0.016). Conclusions: Serum TgAb levels measured at 6-12 months after remnant ablation could predict recurrence in patients with undetectable Tg values. In patients with undetectable Tg and positive TgAb values, a change in TgAb concentration during the early postoperative period may be a prognostic indicator of recurrence. (J Clin Endocrinol Metab 93: 4683-4689, 2008)
引用
收藏
页码:4683 / 4689
页数:7
相关论文
共 26 条
[1]  
Adil Allah- Rakha, 2003, J Coll Physicians Surg Pak, V13, P504
[2]  
[Anonymous], 2003, THYROID, V13, P3
[3]  
[Anonymous], 2007, R LANGUAGE ENV STAT
[4]   Is diagnostic iodine-131 scanning useful after total thyroid ablation for differentiated thyroid cancer? [J].
Cailleux, AF ;
Baudin, E ;
Travagli, JP ;
Ricard, M ;
Schlumberger, M .
JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM, 2000, 85 (01) :175-178
[5]   Disappearance of humoral thyroid autoimmunity after complete removal of thyroid antigens [J].
Chiovato, L ;
Latrofa, F ;
Braverman, LE ;
Pacini, F ;
Capezzone, M ;
Masserini, L ;
Grasso, L ;
Pinchera, A .
ANNALS OF INTERNAL MEDICINE, 2003, 139 (05) :346-351
[6]   Clinical significance of elevated level of serum antithyroglobulin antibody in patients with differentiated thyroid cancer after thyroid ablation [J].
Chung, JK ;
Park, YJ ;
Kim, TY ;
So, Y ;
Kim, SK ;
Park, DJ ;
Lee, DS ;
Lee, MC ;
Cho, BY .
CLINICAL ENDOCRINOLOGY, 2002, 57 (02) :215-221
[7]   A HIGH PREVALENCE OF THYROGLOBULIN AUTOANTIBODIES IN ADULTS WITH AND WITHOUT THYROID-DISEASE AS MEASURED WITH A SENSITIVE SOLID-PHASE IMMUNOSORBENT RADIOASSAY [J].
ERICSSON, UB ;
CHRISTENSEN, SB ;
THORELL, JI .
CLINICAL IMMUNOLOGY AND IMMUNOPATHOLOGY, 1985, 37 (02) :154-162
[8]   Development and clinical impact of thyroglobulin antibodies in patients with differentiated thyroid carcinoma during the first 3 years after thyroidectomy [J].
Görges, R ;
Maniecki, M ;
Jcntzen, W ;
Sheu, SNY ;
Mann, K ;
Bockisch, A ;
Janssen, OE .
EUROPEAN JOURNAL OF ENDOCRINOLOGY, 2005, 153 (01) :49-55
[9]   Thyroglobulin antibodies in differentiated thyroid cancer [J].
Hjiyiannakis, P ;
Mundy, J ;
Harmer, C .
CLINICAL ONCOLOGY, 1999, 11 (04) :240-244
[10]   Coexisting chronic lymphocytic thyroiditis and papillary thyroid cancer revisited [J].
Kebebew, E ;
Treseler, PA ;
Ituarte, PHG ;
Clark, OH .
WORLD JOURNAL OF SURGERY, 2001, 25 (05) :632-637